  The COVID-19 pandemic has had and continues to have major impacts on planned
and ongoing clinical trials. Its effects on trial data create multiple
potential statistical issues. The scale of impact is unprecedented, but when
viewed individually, many of the issues are well defined and feasible to
address. A number of strategies and recommendations are put forward to assess
and address issues related to estimands, missing data, validity and
modifications of statistical analysis methods, need for additional analyses,
ability to meet objectives and overall trial interpretability.
